Aduro Biotech, Inc. is an immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases. ADRO's technology platforms, which are designed to harness the body's natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases.
ADRO's STING Pathway Activator platform is designed to activate the STING receptor in immune cells, resulting in a potent tumor-specific immune response. ADU-S100 is the first STING Pathway Activator compound to enter the clinic and is currently being evaluated in both a Phase 1 monotherapy study as well as a Phase 1b combination study with an anti-PD1 immune checkpoint inhibitor. Aduro’s B-select monoclonal antibody platform is comprised of a number of immune modulating assets in research and development, including BION-1301, an anti-APRIL antibody. ADRO's pLADD program is based on proprietary attenuated strains of Listeria that have been engineered to express tumor neoantigens that are specific to an individual patient’s tumor.
Other Listeria strains for lung and prostate cancers are being advanced by a partner.
Aduro BioTech, Inc. has development and commercialization agreement with Genmab to evaluate five bispecific antibody product candidates targeting immune checkpoints; and collaboration agreement with Janssen Biotech, Inc. and Merck. The company was formerly known as Oncologic, Inc. and changed its name to Aduro BioTech, Inc. in June 2008. Aduro BioTech, Inc. was founded in 2000 and is headquartered in Berkeley, California.
December 18, 2015
RegMed’s close: volume was up and volatility was relatively moderate
December 17, 2015
RegMed’s close: waiting for the “witch”
December 16, 2015
RegMed’s close: Stocks surge but, caution should be your middle name
December 15, 2015
RegMed’s close: my pattern analysis indicated the sector had to be UP
December 14, 2015
RegMed’s close: the sector opened strong to implode by the first half-hour
December 10, 2015
RegMed’s close: why close the barn door when the appreciation is leaving on its own
December 9, 2015
RegMed’s close: mired in disappointment
December 8, 2015
RegMed’s close: rebound and volatility is not a huge surprise
December 8, 2015
Lower open expected. RegMed’s pre-open, more than a few signals resound
December 3, 2015
RegMed’s close: stocks sold-off further into negative territory
35 companies, 1 interpreter!
Insight, foresight and recommendation
Aduro (ADRO) – ADRO started January’18 priced at $7.60, slipping February 1st to $6.25 with 2/16 reflecting a pricing of $6.05 ... with three distinct immunotherapy technologies and VERY early although ADRO has development and commercialization agreement with Genmab to evaluate five bispecific antibody product candidates targeting immune checkpoints; and collaboration agreement with Janssen Biotech, Inc. and Merck th redeeming factor.
buyMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.